Recognition underscores the impact of Medable’s evidence generation platform on clinical research worldwide
Medable was awarded ‘Best Digital Health Solution’ from a field of 24 nominees at the Prix Galien USA Forum in New York City. Worldwide, the Prix Galien Award is regarded as the equivalent of the Nobel Prize for the life science industry. Past winners include such respected companies as Pfizer, Roche Diagnostics, Novartis, Merck & Co., AbbVie, and more.
Medable’s platform is currently trusted by 14 of the top 20 world’s largest pharmaceutical companies and 9 of the top 10 largest Contract Research Organizations (CROs). Medable’s customers have achieved impressive results with decentralized and hybrid trials – including 200 percent faster enrollment and 50 percent cost reductions.
“This recognition is a tremendous honor and validation of Medable’s unwavering commitment to ushering in a new era of drug development – one that merges technology and science to make treatments accessible to everyone, everywhere,” said Medable CEO and co-founder Dr. Michelle Longmire. “Congratulations to all the nominees. We look forward to continuously working with industry leaders and partners to accelerate the journey from scientific discovery to real-world impact, and further propel human progress.”
The Prix Galien Awards are organized by the Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences. "Each year, the Awards Committee is astounded by the growing number of applicants and the level of passion, creativity and determination from the nominees who are developing their ideas into highly desirable solutions for patients around the world. We applaud their unwavering commitment to improving the human condition and are honored to celebrate their achievements," said Bernard Poussot, Prix Galien Committee Chair (Categories: Medical Technology, Startups; Digital Health; and Incubators, Accelerators and Equity), Board Member, Roche Holding & Cargill Inc. Former Chairman & CEO, Wyeth.
Clinical research is burdened with antiquated processes that can extend study timelines, limit patients’ access and participation, and provide inadequate data volume with poor quality, ultimately negatively impacting health outcomes. Medable’s flexible software-as-a-service platform improves the speed, efficiency, and accessibility of research across all therapeutic areas. Medable has deployed its platform in more than 300 clinical trials in 60 countries and 100+ local languages, touching the lives of more than one million patients and research participants globally.
A 2022 financial modeling of DCTs using industry benchmark and Medable data and conducted by the Tufts Center for the Study of Drug Development shows that, on average, decentralized trials can achieve net financial benefits ranging from five to 13 times for Phase II and Phase III trials, due to reduced trial timelines and other factors.
About the Galien Foundation
The Galien Foundation fosters, recognizes, and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatments and technologies that will impact the state of medical practice and save lives.
The Foundation oversees and directs activities in the US for the Prix Galien, an international awards program dedicated to progress through innovative medicines development, with chapters in 14 countries and Africa. The Prix Galien was created in 1970 by Roland Mehl in honor of Galien, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.
About Medable
Medable is on a mission to get effective therapies to patients faster by transforming clinical drug development with disruptive technologies. The company’s digital platform streamlines design, recruitment, retention, and data quality for decentralized trials, replacing siloed systems with integrated digital tools, data and interfaces to accelerate trial execution. Medable connects patients, sites, and clinical trial teams to improve patient access, experience, and outcomes. Medable’s software has been named a Leader in the industry by both Everest Group and IDC. Medable is a privately held, venture-backed company headquartered in Palo Alto, California.
